| Nicolas Manuel Lopez-hisijos, DO | |
|
3601 The Vanderbilt Clinic, Nashville, TN 37232-3825 | |
| (615) 322-5000 | |
| Not Available |
| Full Name | Nicolas Manuel Lopez-hisijos |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 10 Years |
| Location | 3601 The Vanderbilt Clinic, Nashville, Tennessee |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053738195 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZH0000X | Pathology - Hematology | 036.151329 (Illinois) | Secondary |
| 207ZH0000X | Pathology - Hematology | 5053 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vanderbilt University Medical Center | Nashville, TN | Hospital |
| Jackson-madison County General Hospital | Jackson, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Vanderbilt University Medical Center | 5092023416 | 2711 |
News Archive
MorphoSys AG and Boehringer Ingelheim announced today the signing of a biopharmaceutical manufacturing agreement for therapeutic antibodies. The agreement covers the process development and manufacturing of additional clinical material for MorphoSys's proprietary MOR208 program and other drug candidates. MOR208, a potent monoclonal anti-CD19 antibody, is in development for the treatment of chronic lymphocytic leukemia and potentially other B-cell malignancies. The program is currently being evaluated in a phase 1 clinical trial in the USA by MorphoSys's partner Xencor Inc.
With a total nearly $5 billion, Lipitor, a cholesterol-reducing drug, ranked first in terms of total spending on prescription medicines by adults ages 18 to 64 in 2004, and another cholesterol-fighting drug, Zocor, ranked fourth at $2.3 billion, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
Genzyme Corp., a subsidiary of sanofi-aventis Group, today reported additional five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial showing that nearly two-thirds of alemtuzumab treated patients remained free of clinically-active disease as much as four years after most patients received their last course of the investigational drug.
Ohm Laboratories, Inc., a wholly owned subsidiary of Ranbaxy Laboratories Limited, announced today that Ohm has received approval from the U.S. Food and Drug Administration to manufacture and market Valsartan 40 mg, 80 mg, 160 mg, and 320 mg tablets on an exclusive basis.
› Verified 3 days ago
| Entity Name | Vanderbilt University Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104202761 PECOS PAC ID: 5092023416 Enrollment ID: O20151006000369 |
News Archive
MorphoSys AG and Boehringer Ingelheim announced today the signing of a biopharmaceutical manufacturing agreement for therapeutic antibodies. The agreement covers the process development and manufacturing of additional clinical material for MorphoSys's proprietary MOR208 program and other drug candidates. MOR208, a potent monoclonal anti-CD19 antibody, is in development for the treatment of chronic lymphocytic leukemia and potentially other B-cell malignancies. The program is currently being evaluated in a phase 1 clinical trial in the USA by MorphoSys's partner Xencor Inc.
With a total nearly $5 billion, Lipitor, a cholesterol-reducing drug, ranked first in terms of total spending on prescription medicines by adults ages 18 to 64 in 2004, and another cholesterol-fighting drug, Zocor, ranked fourth at $2.3 billion, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
Genzyme Corp., a subsidiary of sanofi-aventis Group, today reported additional five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial showing that nearly two-thirds of alemtuzumab treated patients remained free of clinically-active disease as much as four years after most patients received their last course of the investigational drug.
Ohm Laboratories, Inc., a wholly owned subsidiary of Ranbaxy Laboratories Limited, announced today that Ohm has received approval from the U.S. Food and Drug Administration to manufacture and market Valsartan 40 mg, 80 mg, 160 mg, and 320 mg tablets on an exclusive basis.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicolas Manuel Lopez-hisijos, DO 3841 Green Hills Village Dr Ste 200, Nashville, TN 37215-2691 Ph: (615) 322-5000 | Nicolas Manuel Lopez-hisijos, DO 3601 The Vanderbilt Clinic, Nashville, TN 37232-3825 Ph: (615) 322-5000 |
News Archive
MorphoSys AG and Boehringer Ingelheim announced today the signing of a biopharmaceutical manufacturing agreement for therapeutic antibodies. The agreement covers the process development and manufacturing of additional clinical material for MorphoSys's proprietary MOR208 program and other drug candidates. MOR208, a potent monoclonal anti-CD19 antibody, is in development for the treatment of chronic lymphocytic leukemia and potentially other B-cell malignancies. The program is currently being evaluated in a phase 1 clinical trial in the USA by MorphoSys's partner Xencor Inc.
With a total nearly $5 billion, Lipitor, a cholesterol-reducing drug, ranked first in terms of total spending on prescription medicines by adults ages 18 to 64 in 2004, and another cholesterol-fighting drug, Zocor, ranked fourth at $2.3 billion, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
Genzyme Corp., a subsidiary of sanofi-aventis Group, today reported additional five-year patient data from its completed Phase 2 multiple sclerosis (MS) trial showing that nearly two-thirds of alemtuzumab treated patients remained free of clinically-active disease as much as four years after most patients received their last course of the investigational drug.
Ohm Laboratories, Inc., a wholly owned subsidiary of Ranbaxy Laboratories Limited, announced today that Ohm has received approval from the U.S. Food and Drug Administration to manufacture and market Valsartan 40 mg, 80 mg, 160 mg, and 320 mg tablets on an exclusive basis.
› Verified 3 days ago
Dr. Digna Saunders Forbes, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 1005 Dr. D. B. Todd Blvd, Nashville, TN 37208 Phone: 615-327-6438 Fax: 615-327-5634 | |
Mary Ann Arildsen, MD, PHD Pathology Medicare: Accepting Medicare Assignments Practice Location: 3601 Tvc, Nashville, TN 37232 Phone: 615-322-3000 | |
Eszter Szentirmai, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-3000 | |
Dr. Henry Douglas Edwards, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 2010 Church St, Ste 615, Nashville, TN 37203 Phone: 615-284-7950 Fax: 615-284-5750 | |
Dr. Robert Eugene Burnette, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 1005 Dr. D. B. Todd Blvd, Nashville, TN 37208 Phone: 615-327-6212 Fax: 615-327-6409 | |
James Chappell, MD, PHD Pathology Medicare: Not Enrolled in Medicare Practice Location: 3601 Tvc, Nashville, TN 37232 Phone: 615-322-3000 | |
Dr. Andy Lo, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 2601 Tvc, Nashville, TN 37232 Phone: 615-322-4916 |